The app will first be tested in a pilot study among 20 patients with different cancer diagnosis and eventually in a randomized controlled trial with a sample of 260 patients with different cancer diagnosis. The participants will be randomly assigned to use the 10 module app or to a control group that receive treatment as usual, and followed with repeated measures over 12 months.